Comparative Pharmacology
Head-to-head clinical analysis: RONDOMYCIN versus VIBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RONDOMYCIN versus VIBRAMYCIN.
RONDOMYCIN vs VIBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing addition of amino acids to the growing peptide chain. Bacteriostatic.
150 mg orally twice daily or 300 mg orally once daily.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily; severe infections: 100 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may extend to 20-30 hours in severe renal impairment.
Terminal elimination half-life is 16-18 hours in patients with normal renal function. Prolonged to 20-36 hours in severe renal impairment; no significant change in hepatic impairment.
Renal (40-50% unchanged), biliary/fecal (10-20% as metabolites and unchanged drug). Approximately 30% undergoes enterohepatic circulation.
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-25% eliminated in feces via biliary secretion; remainder metabolized. Renal clearance is about 30 mL/min.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic